Format

Send to

Choose Destination
J Clin Hypertens (Greenwich). 2019 Jul;21(7):991-1001. doi: 10.1111/jch.13563. Epub 2019 Jun 6.

Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.

Author information

1
School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil.
2
Arbor Research Collaborative for Health, Ann Arbor, Michigan.
3
Department of Internal Medicine IV, Saarland University Medical Center, Homburg, Germany.
4
Department of Medicine, University of British Columbia, Vancouver, Canada.
5
Department of Internal Medicine, Michigan Medicine, and Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan.
6
Service de Néphrologie Transplantation Dialyse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
7
Faculdade de Medicina da Bahia School of Medicine, Universidade Federal da Bahia, Brazil.
8
Nephrological Center, Villingen-Schwenningen, Germany.
9
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan.
10
CESP, Center for Research in Epidemiology and Population Health, University Paris-Saclay, University Paris-Sud, UVSQ, Villejuif, France.
11
Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne, Billancourt/Paris, France.

Abstract

Renin-angiotensin-aldosterone system inhibitors (RAASi) are recommended for chronic kidney disease (CKD) patients. In this study, we describe RAASi prescription patterns in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) in Brazil, Germany, France, and the United States (US). 5870 patients (mean age 66-72 years; congestive heart failure [CHF] in 11%-19%; diabetes in 43%-54%; serum potassium ≥5 in 20%-35%) were included. RAASi prescription was more common in Germany (80%) and France (77%) than Brazil (66%) and the United States (52%), where the prevalence of prescription decreases particularly in patients with CKD stage 5. In the multivariable regression model, RAASi prescription was least common in the United States and more common in patients who were younger, had diabetes, hypertension, or less advanced CKD. In conclusion, RAASi prescription patterns vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, even among patients with strong class-specific recommendations. Although the reasons for this variation could not be fully identified in this cross-sectional observation, our data indicate that the risk of hyperkalemia may contribute to the underuse of this class of agents in moderate to advanced CKD.

KEYWORDS:

albuminuria; chronic kidney disease; diabetes; heart failure; renin-angiotensin-aldosterone system inhibitors

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center